DFO
OLMA icon

Duquesne Family Office’s Olema Pharmaceuticals OLMA Stock Holding History

Duquesne Family Office’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.7M Buy
+986,827
New +$22M 0.44% 47

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Duquesne Family Office's OLMA Position: Q1 2026 in Review

Duquesne Family Office opened a new position in Olema Pharmaceuticals (OLMA) in Q1 2026: 986,827 shares worth $14.7M. The stake represents 0.44% of the portfolio and ranks #47 among its holdings.

195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Duquesne Family Office held 986,827 shares of Olema Pharmaceuticals worth $14.7M as of Q1 2026.
  • Olema Pharmaceuticals was a new Duquesne Family Office position in Q1 2026.
  • Olema Pharmaceuticals made up 0.44% of Duquesne Family Office's portfolio in Q1 2026, its #47 holding.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Duquesne Family Office's 13F filing for Q1 2026, filed 15 May 2026.